To evaluate the potential of SET inhibition for treatment of prostate cancer driven by oncogenic PI3K-Akt signaling, we tested the therapeutic effects of OP449 in treatment of an established Pten−/− murine prostate cancer (CaP8) cell line25. Here, PTEN is linked to prostate cancer.